Barclays Maintains an 'Equalweight' on Tech Data (TECD); Cutting Estimates as Weak Margins Make Surprise
Tweet
Share
E-mailGet Alerts TECD Hot Sheet
Price: $144.90 --0%
Rating Summary:
4 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
4 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Tech Data (NASDAQ: TECD) price target of $52.00 (from $53.00).
Analyst, Ben A. Reitzes, said, "The F2Q margins were quite a surprise for TECD and it is unclear exactly how quickly margins can improve from here as SAP and pricing issues could linger. The mix shift toward tablets bears watching as well. The clear positive is top-line results and guidance above estimates by over $100 million each quarter given better than expected European sales."
FY13 EPS estimate lowered from $5.61 to $5.18, FY14 from $5.98 to $5.75 and FY15 from $6.40 to $6.22.
For an analyst ratings summary and ratings history on Tech Data click here. For more ratings news on Tech Data click here.
Shares of Tech Data closed at $49.24 yesterday.
Analyst, Ben A. Reitzes, said, "The F2Q margins were quite a surprise for TECD and it is unclear exactly how quickly margins can improve from here as SAP and pricing issues could linger. The mix shift toward tablets bears watching as well. The clear positive is top-line results and guidance above estimates by over $100 million each quarter given better than expected European sales."
FY13 EPS estimate lowered from $5.61 to $5.18, FY14 from $5.98 to $5.75 and FY15 from $6.40 to $6.22.
For an analyst ratings summary and ratings history on Tech Data click here. For more ratings news on Tech Data click here.
Shares of Tech Data closed at $49.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- NetEase.com (NTES) PT Lowered to $143 at Macquarie
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
